新开源 reported revenue of ¥0.68B for the period ended 2026-06-30, +5.3% year on year. Net income was ¥0.10B, a 15.0% net margin on a 39.3% gross margin. The largest revenue line is PVP其他 at 41% of the total. Free cash flow for the period was ¥0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.68B | +5.3% |
| Gross profit | ¥0.27B | — |
| Operating income | ¥0.12B | — |
| Net income | ¥0.10B | -26.2% |
| Gross margin | 39.3% | Net margin 15.0% |
| Revenue Q/Q | -1.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| PVP其他 | ¥0.28B | 41.0% |
| PVPK30粉 | ¥0.21B | 30.4% |
| 欧瑞姿系列 | ¥0.07B | 10.8% |
| PVP-I | ¥0.05B | 7.3% |
| 精准医疗服务 | ¥0.03B | 4.7% |
| 基因检测技术服务 | ¥0.02B | 2.7% |
| 肿瘤早期诊断 | ¥0.02B | 2.5% |
| 分子诊断服务 | ¥0.00B | 0.6% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.41B | 60.7% |
| R&D | ¥0.04B | 6.0% |
| SG&A | ¥0.09B | 13.5% |
| Tax & other | ¥0.02B | 2.5% |
| Item | Amount |
|---|---|
| Total assets | ¥4.28B |
| Total liabilities | ¥0.96B |
| Shareholders' equity | ¥3.32B |
| Equity / assets | 77.5% |
| Operating cash flow | ¥0.03B |
| Capital expenditure | ¥0.02B |
| Free cash flow | ¥0.01B |
| Cash conversion (OCF / net income) | 98% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
华仁药业 ・ 向日葵 ・ 万讯自控 ・ 顺网科技 ・ 长盈精密 ・ 东方日升 ・ 瑞普生物 ・ 经纬辉开 ・ 阳谷华泰 ・ ST亚光 ・ 聆达股份 ・ 锐奇股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies